AstraZeneca (HAM:ZEG) Tariff Resilience Score: 9/10 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:ZEG AstraZeneca PLC HAM:ZEG
88 GF Score
Price €145.10
GF Value €157.83
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Tariff Resilience Score?

AstraZeneca HAM:ZEG -2.03% 88 Tariff Resilience Score is 9 as of Jul. 15, 2026. GuruFocus rates HAM:ZEG with a GF Score™ of 88/100 and a GF Value™ of €157.83 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,029 Drug Manufacturers companies, AstraZeneca ranks better than 99.9% on this metric.

AstraZeneca has the Tariff Resilience Score of 9, which implies that the company might have Highly Resilient.

AstraZeneca has AstraZeneca has a robust global supply chain with manufacturing in multiple regions, reducing tariff impact. Its diverse product portfolio and strong pricing power provide resilience. Historical tariff changes have had limited effect on operations.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes AstraZeneca might have Highly Resilient.

AstraZeneca  (HAM:ZEG) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

AstraZeneca Tariff Resilience Score Related Terms

HAM:ZEG vs LLY, JNJ, ABBV: Tariff Resilience Score Comparison

For the Drug Manufacturers - General subindustry, AstraZeneca's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AstraZeneca Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Tariff Resilience Score falls into.


HAM:ZEG
88GF Score
AstraZeneca PLC HAM:ZEG
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 9 mean?
AstraZeneca (HAM:ZEG) has a Tariff Resilience Score of 9 as of Jul. 15, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, AstraZeneca ranks #1 out of 1029 companies in the Drug Manufacturers industry, placing it in the top 0.099999999999994%.
Is AstraZeneca's Tariff Resilience Score too high?
AstraZeneca's current Tariff Resilience Score is 9. Based on the distribution chart, AstraZeneca ranks #1 out of 1029 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, AstraZeneca has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's Tariff Resilience Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, AstraZeneca ranks #1 out of 1029 companies for Tariff Resilience Score. This places AstraZeneca in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. AstraZeneca's current Tariff Resilience Score is 9. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca (HAM:ZEG) is currently considered Fairly Valued. The stock's GF Value™ is €157.83, compared to a current price of €145.10 — trading 8.1% below its estimated fair value. The current Tariff Resilience Score is 9. AstraZeneca's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For AstraZeneca (HAM:ZEG), the current Tariff Resilience Score is 9 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca (HAM:ZEG) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of €145.10 is trading 8.1% below its estimated GF Value™ of €157.83. GuruFocus considers AstraZeneca to be Fairly Valued.

Key valuation signals for HAM:ZEG:

  • Tariff Resilience Score: 9
  • GF Value™: €157.83 vs. price of €145.10 (8.1% below fair value)
  • GF Score™: 88/100 with 1 warning sign

No single metric tells the full story. See the HAM:ZEG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
88GF Score

Get the complete analysis for HAM:ZEG

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€145.10
Price
€157.83
GF Value